世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

神経内分泌腫瘍(NETs)治療 - 世界市場シェア・ランキング、全体売上高・需要予測 2024-2030


Neuroendocrine Tumors (NETs) Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

ニューロ・エモーショナル・テクニック(NET)は、ストレス関連反応の生理学的基盤に基づいた心理情動療法である。1970年代後半に発見されたように、情動反応は神経ペプチド(アミノ酸鎖)とその受容体で構成されて... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年3月1日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

ニューロ・エモーショナル・テクニック(NET)は、ストレス関連反応の生理学的基盤に基づいた心理情動療法である。1970年代後半に発見されたように、情動反応は神経ペプチド(アミノ酸鎖)とその受容体で構成されており、それらは体内の離れた組織のニューロンやその他の細胞に存在する。神経ペプチドはニューロンから放出され、コード化された「情報」を体内の他の部位に運ぶ。これらの神経ペプチドは、情報物質(IS)として知られる神経化学物質のカテゴリーに属する。ISはストレス関連の覚醒時に放出され、遠隔に位置する神経受容体に付着する。
神経内分泌腫瘍(NETs)治療の世界市場は、2023年には百万米ドル規模になると推定され、2024年から2030年の予測期間中に年平均成長率(CAGR)%で2030年までに百万米ドルに再調整されると予測されている。

世界の医薬品市場は2022年に1,475億米ドルで、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。

レポートの範囲
本レポートは、神経内分泌腫瘍(NETs)治療薬の世界市場を包括的に紹介することを目的とし、総販売量、販売収益、価格、主要企業の市場シェアおよびランキングに焦点を当て、神経内分泌腫瘍(NETs)治療薬の地域別・国別、タイプ別、用途別の分析も併せて掲載しています。
神経内分泌腫瘍(NETs)治療薬市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データおよび予測データとともに、販売数量(Kユニット)および販売収益(百万ドル)で提供されます。量的および質的分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、神経内分泌腫瘍(NETs)治療に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
先進加速器アプリケーション
AVEOオンコロジー
ベーリンガーインゲルハイムインターナショナル
ハチソン・メディファーマ
イプセンファーマ
ノバルティスAG
ファイザー
プロジェニクス・ファーマシューティカルズ
タイプ別セグメント
ソマトスタチンアナログ(SSAs)
標的治療薬
その他
用途別セグメント
病院
クリニック
その他
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

各章の概要
第1章: レポートのスコープ、世界の総市場規模(バルブ、数量、価格)を紹介します。また本章では、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章 神経内分泌腫瘍(NETs)治療メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。
第3章:タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性を網羅し、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助ける。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第5章:神経内分泌腫瘍(NETs)治療薬の地域別売上高、収益。各地域の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、市場規模を紹介しています。
第6章 神経内分泌腫瘍(NETs)治療の国別売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品の売上高、収益、価格、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Neuroendocrine Tumors (NETs) Treatment Product Introduction
1.2 Global Neuroendocrine Tumors (NETs) Treatment Market Size Forecast
1.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value (2019-2030)
1.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume (2019-2030)
1.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Price (2019-2030)
1.3 Neuroendocrine Tumors (NETs) Treatment Market Trends & Drivers
1.3.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
1.3.2 Neuroendocrine Tumors (NETs) Treatment Market Drivers & Opportunity
1.3.3 Neuroendocrine Tumors (NETs) Treatment Market Challenges
1.3.4 Neuroendocrine Tumors (NETs) Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neuroendocrine Tumors (NETs) Treatment Players Revenue Ranking (2023)
2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Company (2019-2024)
2.3 Global Neuroendocrine Tumors (NETs) Treatment Players Sales Volume Ranking (2023)
2.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Company Players (2019-2024)
2.5 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Company (2019-2024)
2.6 Key Manufacturers Neuroendocrine Tumors (NETs) Treatment Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Neuroendocrine Tumors (NETs) Treatment Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Neuroendocrine Tumors (NETs) Treatment
2.9 Neuroendocrine Tumors (NETs) Treatment Market Competitive Analysis
2.9.1 Neuroendocrine Tumors (NETs) Treatment Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Neuroendocrine Tumors (NETs) Treatment Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Tumors (NETs) Treatment as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Somatostatin Analogs (SSAs)
3.1.2 Targeted Therapy
3.1.3 Other
3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type
3.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Type (%) (2019-2030)
3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type
3.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Type (2019-2030)
3.3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Type (%) (2019-2030)
3.4 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application
4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Application (%) (2019-2030)
4.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application
4.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Application (2019-2030)
4.3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Application (%) (2019-2030)
4.4 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region
5.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2019-2024)
5.1.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2025-2030)
5.1.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (%), (2019-2030)
5.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region
5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region (2019-2024)
5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region (2025-2030)
5.2.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region (%), (2019-2030)
5.3 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.4.2 North America Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.5.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.7.2 South America Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.8.2 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Value
6.2.1 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.2.2 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.3.2 United States Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.4.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.5.2 China Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.6.2 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.7.2 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.9.2 India Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Advanced Accelerator Applications
7.1.1 Advanced Accelerator Applications Company Information
7.1.2 Advanced Accelerator Applications Introduction and Business Overview
7.1.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.1.5 Advanced Accelerator Applications Recent Development
7.2 AVEO Oncology
7.2.1 AVEO Oncology Company Information
7.2.2 AVEO Oncology Introduction and Business Overview
7.2.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.2.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.2.5 AVEO Oncology Recent Development
7.3 Boehringer Ingelheim International
7.3.1 Boehringer Ingelheim International Company Information
7.3.2 Boehringer Ingelheim International Introduction and Business Overview
7.3.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.3.5 Boehringer Ingelheim International Recent Development
7.4 Hutchison MediPharma Limited
7.4.1 Hutchison MediPharma Limited Company Information
7.4.2 Hutchison MediPharma Limited Introduction and Business Overview
7.4.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.4.5 Hutchison MediPharma Limited Recent Development
7.5 IpsenPharma
7.5.1 IpsenPharma Company Information
7.5.2 IpsenPharma Introduction and Business Overview
7.5.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.5.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.5.5 IpsenPharma Recent Development
7.6 Novartis AG
7.6.1 Novartis AG Company Information
7.6.2 Novartis AG Introduction and Business Overview
7.6.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.6.5 Novartis AG Recent Development
7.7 Pfizer, Inc
7.7.1 Pfizer, Inc Company Information
7.7.2 Pfizer, Inc Introduction and Business Overview
7.7.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.7.5 Pfizer, Inc Recent Development
7.8 Progenics Pharmaceuticals
7.8.1 Progenics Pharmaceuticals Company Information
7.8.2 Progenics Pharmaceuticals Introduction and Business Overview
7.8.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.8.5 Progenics Pharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Neuroendocrine Tumors (NETs) Treatment Industrial Chain
8.2 Neuroendocrine Tumors (NETs) Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neuroendocrine Tumors (NETs) Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Neuroendocrine Tumors (NETs) Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

Neuro Emotional Technique (NET) is a psycho-emotional therapy based on the physiological foundations of stress-related responses. As discovered in the late 1970’s, emotional responses are composed of neuropeptides (amino acid chains) and their receptors, which lie on neurons and other cells of remote tissues in the body. The neuropeptides are ejected from the neuron and carry the encoded “information” to other sites within the body. These neuropeptides are in a category of neurochemicals known as Information Substances (IS). ISs are released at times of stress-related arousal and become attached to remotely-positioned neuroreceptors.
The global market for Neuroendocrine Tumors (NETs) Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Tumors (NETs) Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Neuroendocrine Tumors (NETs) Treatment by region & country, by Type, and by Application.
The Neuroendocrine Tumors (NETs) Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Tumors (NETs) Treatment.

Market Segmentation
By Company
Advanced Accelerator Applications
AVEO Oncology
Boehringer Ingelheim International
Hutchison MediPharma Limited
IpsenPharma
Novartis AG
Pfizer, Inc
Progenics Pharmaceuticals
Segment by Type:
Somatostatin Analogs (SSAs)
Targeted Therapy
Other
Segment by Application
Hospitals
Clinics
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neuroendocrine Tumors (NETs) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Neuroendocrine Tumors (NETs) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Neuroendocrine Tumors (NETs) Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Neuroendocrine Tumors (NETs) Treatment Product Introduction
1.2 Global Neuroendocrine Tumors (NETs) Treatment Market Size Forecast
1.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value (2019-2030)
1.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume (2019-2030)
1.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Price (2019-2030)
1.3 Neuroendocrine Tumors (NETs) Treatment Market Trends & Drivers
1.3.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
1.3.2 Neuroendocrine Tumors (NETs) Treatment Market Drivers & Opportunity
1.3.3 Neuroendocrine Tumors (NETs) Treatment Market Challenges
1.3.4 Neuroendocrine Tumors (NETs) Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neuroendocrine Tumors (NETs) Treatment Players Revenue Ranking (2023)
2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Company (2019-2024)
2.3 Global Neuroendocrine Tumors (NETs) Treatment Players Sales Volume Ranking (2023)
2.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Company Players (2019-2024)
2.5 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Company (2019-2024)
2.6 Key Manufacturers Neuroendocrine Tumors (NETs) Treatment Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Neuroendocrine Tumors (NETs) Treatment Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Neuroendocrine Tumors (NETs) Treatment
2.9 Neuroendocrine Tumors (NETs) Treatment Market Competitive Analysis
2.9.1 Neuroendocrine Tumors (NETs) Treatment Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Neuroendocrine Tumors (NETs) Treatment Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Tumors (NETs) Treatment as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Somatostatin Analogs (SSAs)
3.1.2 Targeted Therapy
3.1.3 Other
3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type
3.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Type (%) (2019-2030)
3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type
3.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Type (2019-2030)
3.3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Type (%) (2019-2030)
3.4 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application
4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value, by Application (%) (2019-2030)
4.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application
4.3.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Application (2019-2030)
4.3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume, by Application (%) (2019-2030)
4.4 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region
5.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2019-2024)
5.1.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (2025-2030)
5.1.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Value by Region (%), (2019-2030)
5.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region
5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region (2019-2024)
5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region (2025-2030)
5.2.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Volume by Region (%), (2019-2030)
5.3 Global Neuroendocrine Tumors (NETs) Treatment Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.4.2 North America Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.5.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.7.2 South America Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
5.8.2 Middle East & Africa Neuroendocrine Tumors (NETs) Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Value
6.2.1 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.2.2 Key Countries/Regions Neuroendocrine Tumors (NETs) Treatment Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.3.2 United States Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.4.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.5.2 China Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.6.2 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.7.2 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neuroendocrine Tumors (NETs) Treatment Sales Value, 2019-2030
6.9.2 India Neuroendocrine Tumors (NETs) Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neuroendocrine Tumors (NETs) Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Advanced Accelerator Applications
7.1.1 Advanced Accelerator Applications Company Information
7.1.2 Advanced Accelerator Applications Introduction and Business Overview
7.1.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.1.5 Advanced Accelerator Applications Recent Development
7.2 AVEO Oncology
7.2.1 AVEO Oncology Company Information
7.2.2 AVEO Oncology Introduction and Business Overview
7.2.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.2.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.2.5 AVEO Oncology Recent Development
7.3 Boehringer Ingelheim International
7.3.1 Boehringer Ingelheim International Company Information
7.3.2 Boehringer Ingelheim International Introduction and Business Overview
7.3.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.3.5 Boehringer Ingelheim International Recent Development
7.4 Hutchison MediPharma Limited
7.4.1 Hutchison MediPharma Limited Company Information
7.4.2 Hutchison MediPharma Limited Introduction and Business Overview
7.4.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.4.5 Hutchison MediPharma Limited Recent Development
7.5 IpsenPharma
7.5.1 IpsenPharma Company Information
7.5.2 IpsenPharma Introduction and Business Overview
7.5.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.5.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.5.5 IpsenPharma Recent Development
7.6 Novartis AG
7.6.1 Novartis AG Company Information
7.6.2 Novartis AG Introduction and Business Overview
7.6.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.6.5 Novartis AG Recent Development
7.7 Pfizer, Inc
7.7.1 Pfizer, Inc Company Information
7.7.2 Pfizer, Inc Introduction and Business Overview
7.7.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.7.5 Pfizer, Inc Recent Development
7.8 Progenics Pharmaceuticals
7.8.1 Progenics Pharmaceuticals Company Information
7.8.2 Progenics Pharmaceuticals Introduction and Business Overview
7.8.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Offerings
7.8.5 Progenics Pharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Neuroendocrine Tumors (NETs) Treatment Industrial Chain
8.2 Neuroendocrine Tumors (NETs) Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neuroendocrine Tumors (NETs) Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Neuroendocrine Tumors (NETs) Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る